Development of flavivirus subviral particles with low cross-reactivity by mutations of a distinct antigenic domain
-
Published:2023-10-13
Issue:24
Volume:107
Page:7515-7529
-
ISSN:0175-7598
-
Container-title:Applied Microbiology and Biotechnology
-
language:en
-
Short-container-title:Appl Microbiol Biotechnol
Author:
Tabata Koshiro, Itakura Yukari, Ariizumi Takuma, Igarashi Manabu, Kobayashi Hiroko, Intaruck Kittiya, Kishimoto Mai, Kobayashi Shintaro, Hall William W., Sasaki Michihito, Sawa Hirofumi, Orba YasukoORCID
Abstract
Abstract
The most conserved fusion loop (FL) domain present in the flavivirus envelope protein has been reported as a dominant epitope for cross-reactive antibodies to mosquito-borne flaviviruses (MBFVs). As a result, establishing accurate serodiagnosis for MBFV infections has been difficult as anti-FL antibodies are induced by both natural infection and following vaccination. In this study, we modified the most conserved FL domain to overcome this cross-reactivity. We showed that the FL domain of lineage I insect-specific flavivirus (ISFV) has differences in antigenicity from those of MBFVs and lineage II ISFV and determined the key amino acid residues (G106, L107, or F108), which contribute to the antigenic difference. These mutations were subsequently introduced into subviral particles (SVPs) of dengue virus type 2 (DENV2), Zika virus (ZIKV), Japanese encephalitis virus (JEV), and West Nile virus (WNV). In indirect enzyme-linked immunosorbent assays (ELISAs), these SVP mutants when used as antigens reduced the binding of cross-reactive IgG and total Ig induced by infection of ZIKV, JEV, and WNV in mice and enabled the sensitive detection of virus-specific antibodies. Furthermore, immunization of ZIKV or JEV SVP mutants provoked the production of antibodies with lower cross-reactivity to heterologous MBFV antigens compared to immunization with the wild-type SVPs in mice. This study highlights the effectiveness of introducing mutations in the FL domain in MBFV SVPs with lineage I ISFV-derived amino acids to produce SVP antigens with low cross-reactivity and demonstrates an improvement in the accuracy of indirect ELISA-based serodiagnosis for MBFV infections.
Key points
• The FL domain of Lineage I ISFV has a different antigenicity from that of MBFVs.
• Mutated SVPs reduce the binding of cross-reactive antibodies in indirect ELISAs.
• Inoculation of mutated SVPs induces antibodies with low cross-reactivity.
Funder
Japan Agency for Medical Research and Development Japan Society for the Promotion of Science Japan Science and Technology Agency
Publisher
Springer Science and Business Media LLC
Subject
Applied Microbiology and Biotechnology,General Medicine,Biotechnology
Reference66 articles.
1. Andersen LK, Davis MD (2017) Climate change and the epidemiology of selected tick-borne and mosquito-borne diseases: update from the International Society of Dermatology Climate Change Task Force. Int J Dermatol 56(3):252–259. https://doi.org/10.1111/ijd.13438 2. Anderson KB, Gibbons RV, Thomas SJ, Rothman AL, Nisalak A, Berkelman RL, Libraty DH, Endy TP (2011) Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand. PLoS Negl Trop Dis 5(10):e1311. https://doi.org/10.1371/journal.pntd.0001311 3. Auguste AJ, Langsjoen RM, Porier DL, Erasmus JH, Bergren NA, Bolling BG, Luo H, Singh A, Guzman H, Popov VL, Travassos da Rosa APA, Wang T, Kang L, Allen IC, Carrington CVF, Tesh RB, Weaver SC (2021) Isolation of a novel insect-specific flavivirus with immunomodulatory effects in vertebrate systems. Virology 562:50–62. https://doi.org/10.1016/j.virol.2021.07.004 4. Bardina SV, Bunduc P, Tripathi S, Duehr J, Frere JJ, Brown JA, Nachbagauer R, Foster GA, Krysztof D, Tortorella D, Stramer SL, Garcia-Sastre A, Krammer F, Lim JK (2017) Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity. Science 356(6334):175–180. https://doi.org/10.1126/science.aal4365 5. Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, Galarza-Munoz G, McGrath EL, Urrabaz-Garza R, Gao J, Wu P, Menon R, Saade G, Fernandez-Salas I, Rossi SL, Vasilakis N, Routh A, Bradrick SS, Garcia-Blanco MA (2016) A screen of FDA-approved drugs for inhibitors of Zika virus infection. Cell Host Microbe 20(2):259–270. https://doi.org/10.1016/j.chom.2016.07.004
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|